Latest news with #ischemicStroke
Medscape
10 hours ago
- Health
- Medscape
Fast Five Quiz: Migraine Complications and Comorbidities
Migraine is associated with several complications and comorbidities that can significantly impact quality of life. Understanding risk profiles and monitoring for complications is paramount in managing patients living with migraine. What do you know about the complications and comorbidities of migraine? Check your knowledge with this quiz. Ischemic stroke is a complication among patients with migraine, especially among those who experience aura. Although the prevalence of stroke in migraine is relatively low, a recent review found that migraine with aura is consistently associated with higher risk for various cardiovascular complications than migraine without aura, with the evidence being the strongest for ischemic stroke. Lifestyle factors such as smoking and oral contraceptive use have also been found to increase the risk for stroke in patients with migraine. Unilateral frontotemporal pain can be a typical symptom of migraine that is not as strongly associated with ischemic stroke, especially if it is not accompanied by aura; nausea and/or vomiting and mood changes are not strongly associated with ischemic stroke in patients with migraine as well. Learn more about migraine symptoms. Depression and migraine are found to have a bidirectional association, as well as shared genetic factors. Further, depression can be linked to any severity of migraine; patients who are treated for migraine can still experience depression as well. The dysregulation of the hypothalamic and thalamic pathways has been implicated as a possible cause in both diseases. Learn more about depression in migraine. Migrainous infarction is a rare complication that is defined as ischemic infarction in relevant areas occurring in a patient experiencing migraine with aura for over 60 minutes, which can be accounted for by no other International Classification of Headache Disorders (ICHD) diagnosis. Data indicate that migrainous infarction is implicated in up to 1.5% of all ischemic stroke cases and typically occurs in younger (29-39 years) patients. However, when compared with "strokes from traditional risk factors," researchers claim the prognosis for migrainous infarction is generally favorable. Learn more about infarction in migraine. Epilepsy is common in hemiplegic migraine, with one review citing occurrence in approximately 40% of patients with this migraine subtype. It also has a strong genetic component that it shares with epilepsy; several mutations, such as in the CACNA1A, ATP1A2, SCN1A, and PRRT2 genes, are seen in both diseases. As such, there is overlap in symptom presentation and even triggering mechanisms for both migraine and epilepsy, and the electrical signature of both diseases in the brain is similar. Migraine without aura and retinal migraine can cause seizures in some patients, but they are not strongly associated with epilepsy. Migraine with aura is also a known seizure trigger, although not exclusively for epilepsy. Learn more about migraine symptoms and presentation. Sleep disorders such as insomnia, narcolepsy, restless leg syndrome, and obstructive sleep apnea are also associated with migraine, and sleep deprivation is known to be a migraine trigger as well. Data indicate that sleep complaints are more prevalent in patients with chronic migraine, which is consistent with a recent survey finding that headache frequency, but not severity, was associated with insomnia. As headache frequency increases and migraine proceeds to chronification, clinicians should be aware of the potential for further sleep-related quality of life deficits. Learn more about migraine symptoms and presentation. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication.
Associated Press
6 days ago
- Business
- Associated Press
ANACONDA Biomed Receives CE Mark for Its ANA5 Funnel Catheter to Treat Ischemic Stroke
BARCELONA, Spain--(BUSINESS WIRE)--Jun 18, 2025-- ANACONDA Biomed, a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has announced that it has received CE Mark certification for its ANA5 Funnel Catheter. The CE marking confirms that the ANA5 device complies with the European Union's health, safety, and environmental protection standards, enabling its eventual commercial viability across the EU. This press release features multimedia. View the full release here: The ANA5 Funnel Catheter is engineered to optimize mechanical thrombectomy by maximizing clot capture with its vessel-matching diameter funnel. Simultaneously, it enables antegrade flow arrest and offers the potential for flow reversal, enhancing aspiration-assisted clot retrieval. The ANA5 promotes improved clot capture and removal through its unique proprietary geometry. The ANA5 Funnel Catheter is engineered to optimize mechanical thrombectomy by maximizing clot capture with its vessel-matching diameter funnel. Simultaneously, it enables antegrade flow arrest and offers the potential for flow reversal, enhancing aspiration-assisted clot retrieval. The ANA5 promotes improved clot capture and removal through its unique proprietary geometry. The CE Mark approval is supported by a comprehensive body of evidence, including preclinical bench and animal studies, and clinical data from the recently published ANAIS study demonstrating high reperfusion and first-pass success rates. Further clinical validation is ongoing in the ATHENA trial, a prospective, multicenter randomized study systematically evaluating the impact of proximal flow arrest on reperfusion effectiveness, to support future regulatory submissions and commercialization efforts in the United States. ' Receiving CE Mark approval is a pivotal achievement for ANACONDA Biomed thatadvances our mission to innovate in the interventional management of acute ischemic stroke,' said Trent Reutiman, chief executive officer. " This milestone reflects the strength of our science and the dedication of our team. We now have the capability of making ANA5 available to clinicians across Europe, bringing this innovative technology to broader stroke application.' Dr. Marc Ribo, the co-founder of Anaconda Biomed, added, " Receiving CE Mark approval for ANA5 is deeply meaningful, as it represents the culmination of years of research, iteration, and belief in an idea that began at the bench. This is more than a regulatory milestone; it's the moment where innovation becomes impact. We're now gearing up to capture real-world data by collecting more invaluable insight into how ANA5 performs across diverse stroke centers and clinical realities. ' About ANA Funnel Catheter ANA5 Advanced Neurovascular Access™ (ANA Funnel Catheter) is designed as an expandable and collapsable funnel catheter for interventional neurovascular procedures, requiring the retrieval of clot, and benefiting from limiting flow and/or flow reversal towards that goal. The device consists of a radiopaque nitinol braid funnel, covered with a polymeric coating enabling local flow arrest. The catheter is currently an investigational device and is not available for sale in the United States. About Anaconda Biomed Anaconda Biomed is an innovative medical technology company dedicated to developing next-generation thrombectomy systems for the treatment of ischemic stroke. At the heart of its product portfolio is the ANA Funnel Catheter. Anaconda Biomed has received funding from prominent life science investment firms, including Ysios Capital, Omega Funds, Innogest, Asabys Partners, Banco Sabadell, and private investors. Additionally, through public grants, the company has received significant public support from ENISA, CDTI (Innvierte and NEOTEC), the Ministry of Science & Innovation (Emplea and Retos), EIB, and EIT Health. For more information, please visit and follow the company on LinkedIn. View source version on CONTACT: MEDIA CONTACT: Joe Duraes Pazanga Health Communications [email protected] 917-687-6419 KEYWORD: SPAIN EUROPE INDUSTRY KEYWORD: SURGERY MEDICAL DEVICES HEALTH CLINICAL TRIALS CARDIOLOGY SOURCE: Anaconda Biomed Copyright Business Wire 2025. PUB: 06/18/2025 07:05 AM/DISC: 06/18/2025 07:03 AM
